<table border="1"><tr><th>Beurs</th><td>NYSE | LLY</td></tr><tr><th>Oprichting</th><td>1876</td></tr><tr><th>Oprichter(s)</th><td>Eli Lilly</td></tr><tr><th>Sleutelfiguren</th><td>David A. Ricks, | (CEO &amp; voorzitter)</td></tr><tr><th>Hoofdkantoor</th><td> Indianapolis</td></tr><tr><th>Werknemers</th><td>38.680 | (2018)</td></tr><tr><th>Producten</th><td>Fluoxetine | Humalog | Tadalafil | Atomoxetine | Dextropropoxyphene</td></tr><tr><th>Industrie</th><td>Farmaceutisch | Gezondheidszorg</td></tr><tr><th>Omzet/jaar</th><td>US$ 24.556 miljoen | (2018)</td></tr><tr><th>Winst/jaar</th><td>US$ 3232 miljoen | (2018)</td></tr><tr><th>Marktkapitalisatie</th><td>US$ 107 miljard | (20 aug. 2019)</td></tr><tr><th>Website</th><td>www.lilly.com</td></tr><tr><th>Portaal</th><td>Economie</td></tr></table>